United Kingdom-Runcorn: Pharmaceutical products

To get tender notifications and more sign up now and never miss a notice again.

Tile United Kingdom-Runcorn: Pharmaceutical products
OJEU (High Value) 591007-2019
Type Invitation to tender
Date Published 2019-12-13
Deadline 2020-01-15 13:00:00
Nature Of Contract Supply contract
Awarding Authority Centeral Government
Awarding Criteria The most economic tender
Procedure Open procedure

Description :
CONTRACT NOTICE


Section I: Contracting authority

I.1) Name and addresses:
Official name: The NHS Commissioning Board (operating under the name of NHS England)
Postal address: 2nd Floor, Rutland House
Town: Runcorn
Postal code: WA7 2ES
Country: UK
Telephone: +44 7730380490
E-mail: lynne.tierney@nhs.net
NUTS code: UK
Main address (URL): https://nhsengland.bravosolution.co.uk
I.2.3) The contract is awarded by a central purchasing body

Communication
I.3) Procurement documents
(URL):https://nhsengland.bravosolution.co.uk

Additional Information
I.3.4) Additional information can be obtained from:
I.3.6)Tenders or requests to participate must be submitted electronically via:
https://nhsengland.bravosolution.co.uk
I.3.8) to the above mentioned address
I.4) Type of the contracting authority: MINISTRY

Main Activity
I.5.1) Main Activity: HEALTH

Section II: Object of Contract


Title:

NHS National Pharmaceuticals Transition 2020_1

Reference number: CM/PHG/19/5586

II.1.4) Short description

Invitation to offer for NHS National Pharmaceuticals Transition 2020_1

Offer reference number: CM/PHG/19/5586

Period of framework agreement: the total maximum duration of the framework agreement to be no more than 42 months.

Potential periods of call-offs under the framework agreement:

LSNE: 4.5.2020 to 31.1.2022 (21 months);

CESW: 4.5.2020 to 31.1.2021 (9 months);

NWLN: 4.5.2020 to 31.7.2021 (15 months).

Products on the framework include (but are not limited to):

Aliskiren

Aprepitant

Arsenic

Atazanavir

Atomoxetine

Bortezomib

Carglumic

Clofarabine

Darunavir

Dexmedetomidine

Dexrazoxane

Erlotinib

Exenatide

Irinotecan

Ganciclovir

Gefitinib

Irinotecan

Labetalol

Melatonin

Metaraminol

Methylthioninium

Miglustat

Olopatadine

Ritonavir

Solifenacin

Temsirolimus

Thalidomide

Tipranavir

Trabectedin

Ziconotide

Details of presentation sizes and volumes are within the tender document set.

II.01) Estimated value excluding VAT:
GBP 96000000.00

Information about lots
II.1.6) This contract is divided into lots: yes



Description: Item/Lot 1
Title:

LSNE: 4.5.2020 to 31.1.2022 (21 Months)

II.2.1) Lot No: 1
NUTS code: UK
II.2.3.2) Main site or place of performance:

Please refer to Document 3, Schedule 8 in the ITO Documents for the list of purchasing points.

II.1.4) Short description

NHS National Pharmaceuticals Transition 2020_1

Offer reference number: CM/PHG/19/5586

Period of framework agreement: the total maximum duration of the framework agreement to be no more than 42 months.

Potential periods of call-offs under the framework agreement:

LSNE: 4.5.2020 to 31.1.2022 (21 months);

CESW: 4.5.2020 to 31.1.2021 (9 months);

NWLN: 04.5.2020 to 31.7.2021 (15 months).

II.2.5) Award criteria:

Value excluding VAT: GBP 45000000.00
II.2.6) Duration of the contract, framework agreement or dynamic purchasing system
II.2.7) Start 2020-05-04
II.2.7) End 2022-01-31
II.2.7.5) This contract is subject to renewal: no
II.2.10) Variants will be accepted: no
II.2.11) Options
II.2.11.2) Description of options

This framework has options for the LSNE region to extend for up to a maximum of a further 21 months.



Description: Item/Lot 2
Title:

CESW: 4.5.2020 to 31.1.2021 (9 Months)

II.2.1) Lot No: 2
NUTS code: UK
II.1.4) Short description

NHS National Pharmaceuticals Transition 2020_1

Offer reference number: CM/PHG/19/5586

Period of framework agreement: the total maximum duration of the framework agreement to be no more than 42 months.

Potential periods of call-offs under the framework agreement:

LSNE: 4.5.2020 to 31.1.2022 (21 months);

CESW: 4.5.2020 to 31.1.2021 (9 months);

NWLN: 4.5.2020 to 31.7.2021 (15 months).

II.2.5) Award criteria:

Value excluding VAT: GBP 19000000.00
II.2.6) Duration of the contract, framework agreement or dynamic purchasing system
II.2.7) Start 2020-05-04
II.2.7) End 2021-01-31
II.2.7.5) This contract is subject to renewal: no
II.2.10) Variants will be accepted: no
II.2.11) Options
II.2.11.2) Description of options

This framework has options for the CESW region to extend for up to a maximum of a further 9 months.



Description: Item/Lot 3
Title:

NWLN: 4.5.2020 to 31.7.2021 (15 Months)

II.2.1) Lot No: 3
NUTS code: UK
II.1.4) Short description

NHS National Pharmaceuticals Transition 2020_1

Offer reference number: CM/PHG/19/5586

Period of framework agreement: the total maximum duration of the framework agreement to be no more than 42 months.

Potential periods of call-offs under the framework agreement:

LSNE: 4.5.2020 to 31.1.2022 (21 months);

CESW: 4.5.2020 to 31.1.2021 (9 months);

NWLN: 4.5.2020 to 31.7.2021 (15 months).

II.2.5) Award criteria:

Value excluding VAT: GBP 32000000.00
II.2.6) Duration of the contract, framework agreement or dynamic purchasing system
II.2.7) Start 2020-05-04
II.2.7) End 2021-07-31
II.2.7.5) This contract is subject to renewal: no
II.2.10) Variants will be accepted: no
II.2.11) Options
II.2.11.2) Description of options

This framework has options for the NWLN region to extend for up to a maximum of a further 15 months.



Section IV: Procedure

IV.1.1) Type of procedure: Open
IV.1.3) The procurement involves the establishment of a framework agreement


IV.02.01) Time limit for receipt of tenders or requests to participate
IV.02.02) Date 2020-01-15
IV.02.02) Local time 13:00


IV.02.07) Conditions for opening of tenders
IV.02.07) Date 2020-01-15
IV.02.07) Local time 13:00
IV.02.07) Place

Runcorn.


Additional information:

Commercial medicines unit employee.


Section V: Complementary information


VI.2.1) Electonic ordering will be used
VI.2.2) Electronic invoicing will be accepted
VI.2.3) Electronic payment will be used

Additional information:

Responding to this notice;

Any supplier may be disqualified who does not respond to the following in the requisite manner:

1) Submission of expression of interest and procurement specific information.

This procurement exercise will be conducted on the eTendering portal at https://nhsengland.bravosolution.co.uk

Candidates wishing to be considered for this procurement exercise must register and provide additional procurement specific information (if requested), through the eTendering portal as follows:

1.1) If not already registered, candidates should register on the eTendering portal at https://nhsengland.bravosolution.co.uk/web/login.html and click the link to register:

— accept the terms and conditions and click continue,

— enter your correct business and user details,

— note the username you chose and click ‘Save’ when complete,

— you will shortly receive an email with your unique password (please keep this secure).

1.2) Once registered, candidates must express interest as follows:

(a) login to the eTendering portal;

(b) select ‘Response to ITT’;

(c) select ‘ITTs Open To All Suppliers’;

(d) access listing related to this procurement, NHS National Pharmaceuticals Transition 2020_1 and view details;

(e) click on ‘Express interest’ button at the top of the page;

(f) once you have expressed interest, the ITT will move to ‘My ITTs’, where you can download additional documentation (if required) and construct your reply as instructed. You must then publish your reply using the ‘Publish’ button.

1.3) For any support in registering on the portal or submitting your expression of interest please contact the eTendering help-desk at +44 8003684850 or help@bravosolution.co.uk

2) General supplier information.

To manage and assess supplier information the contracting authority requests candidates provide their company profile in the Government's Supplier Registration Service (which has replaced sid4gov), as follows:

2.1) If not already registered (the previous sid4gov password, login and details will still be on the system), candidates must go to the following web page https://supplierregistration.cabinetoffice.gov.uk and select ‘Register’ at the top of the page. Key in details as requested to search for your company. If you do not have a D-U-N-S® number, click on the link at the right of the page to obtain a number from D&B. Candidates must obtain a Dun and Bradstreet (D&B) D-U-N-S® number to enable registration on the system;

2.2) Once registration is complete you are able to create and update your company profile. Candidates should ensure all the mandatory fields of their profile are completed and up to date for each procurement exercise. D&B data will be supplied automatically by D&B;

2.3) For further help or information concerning sid4gov, please contact the sid4gov Helpdesk at: support@nqc.com or telephone +44 (0) 8452992994.

Other contracting authorities.

The framework agreement is for the benefit of other participating NHS bodies (whether acting individually, or on behalf of, or together as members of any consortia) along with any other non-NHS bodies which the participants deem necessary for the delivery of services or goods to NHS bodies, local authorities, other Government departments or non-departmental public bodies charged with the delivery of healthcare or health related services.


Review body:
Official name: The Royal Courts of Justice
Town: London or any other district registry of the High Court
Country: UK

Section VI

VI.05.00) Date of dispatch of this notice 2019-12-11

English Language Unavailable

CPV Codes
33600000; 33690000; Pharmaceutical products; Various medicinal products;

Signup now to receive weekly OJEU reports for the UK, your sector and/or elsewhere in the EU. We also report on the procurement of EC Institutions.

All content is copyright (c) htps://www.ojeu.com OJEU Finder Ltd, for more information see our Terms & Conditions